A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study

This multicenter open-label extension study is designed to evaluate the safety and tolerability of lampalizumab intravitreal injections in participants with GA secondary to age-related macular degeneration (AMD) who completed 96 weeks of treatment in Studies GX29176 (NCT02247479) or GX29185 (NCT02247531). The extension will enroll participants from the parent studies who received investigational lampalizumab, as well as lampalizumab-naive participants exposed to sham comparator. All participants will receive open-label lampalizumab in the present study.

开始日期2016-07-21

申办/合作机构

Hoffmann-La Roche, Inc.

PER-003-15

/ Suspended临床3期

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTEREDINTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION

开始日期2015-08-01

申办/合作机构-

PER-076-14

/ Suspended临床3期

开始日期2015-07-06

申办/合作机构-

100 项与 Lampalizumab 相关的临床结果

登录后查看更多信息

100 项与 Lampalizumab 相关的转化医学

登录后查看更多信息

100 项与 Lampalizumab 相关的专利（医药）

登录后查看更多信息

项与 Lampalizumab 相关的文献（医药）

2025-05-01·Ophthalmology science

Reading Performance in Geographic Atrophy: Comparison of Different Reading Speed Measures for Capturing Longitudinal Changes

Article

作者: Wu, Zhichao ; Steffen, Verena ; Guymer, Robyn H ; Harris, Will ; Ferrara, Daniela ; Cukras, Catherine A

Purpose:

To compare different reading speed measures for capturing longitudinal visual function changes in eyes with geographic atrophy (GA) secondary to age-related macular degeneration.

Design:

Analysis of data from Chroma (NCT02247479) and Spectri (NCT02247531), 2 identically designed, phase III, double-masked, randomized controlled clinical trials for lampalizumab.

Participants:

Nine hundred forty participants aged ≥50 years old with bilateral GA, who completed monocular testing of reading speed at ≥3 visits over >1-year follow-up.

Methods:

Monocular reading speed was assessed using the Minnesota Low-Vision Reading Test (MNRead). Four different reading speed measures were derived and compared: reading speed of the fastest sentence read (RS₁), mean reading speed of the 3 fastest sentences read (RS₂), mean reading speed of the sentences larger than the critical print size (RS₃), and mean reading speed of the 10 largest print sizes (termed the Reading Accessibility Index [ACC]).

Main Outcome Measures:

Coefficient of variation (CV), with lower values reflecting better performance of a measure for capturing longitudinal change relative to interindividual variability.

Results:

All 4 reading speed measures showed a significant decline at 48, 72, and 96 weeks from baseline (P < 0.001 for all). The CVs for ACC and RS₂ (204% and 208%, respectively) were lower than for RS₁ (255%; P ≤ 0.002) and RS₃ (224%; P ≥ 0.068) for detecting change from baseline at 48 weeks, but these 2 measures were not significantly different from each other (P = 0.362). There were also statistically significant, but weak, negative correlations between the change from baseline at 48 weeks for all 4 reading speed measures with GA area on fundus autofluorescence imaging (ρ = -0.13 to -0.15; all P < 0.001).

Conclusions:

The mean reading speed derived from either the 10 print sizes found in everyday life (ACC) or the fastest 3 sentences read (RS₂) was better than 2 widely used measures (RS₁ and RS₃) at capturing progressive functional decline in eyes with GA and may be the preferred measures in future clinical trials and studies. All reading speed measures also showed an expected progressive decline over time, but they only showed a weak correlation with GA growth.

Financial Disclosures:

Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

2025-04-01·OPHTHALMOLOGY

Visual Loss in Geographic Atrophy

Article

作者: Schmitz-Valckenberg, Steffen ; Tufail, Adnan ; Csaky, Karl ; Sadda, Srinivas R ; Chakravarthy, Usha ; Kaiser, Peter K. ; Steffen, Verena ; Lad, Eleonora M. ; Kaiser, Peter K ; Sadda, Srinivas R. ; Ferrara, Daniela ; Lad, Eleonora M ; Anegondi, Neha

PURPOSE:

To assess the correlation of lesion growth rate and baseline factors, including foveal involvement and focality, on visual loss as measured by best-corrected visual acuity (BCVA) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

DESIGN:

Retrospective analysis of the lampalizumab phase 3 (NCT02247479 and NCT02247531) and prospective observational (NCT02479386) trials.

PARTICIPANTS:

Patients with bilateral GA.

METHODS:

Monthly BCVA and fundus autofluorescence (FAF) at baseline and every 6 months for 2 years were analyzed. Baseline GA area from FAF images was correlated to baseline BCVA and change in BCVA. The lesion growth rate was calculated as the slope of a linear fit from all available GA area measurements of a patient. The association between GA growth rate quartiles and BCVA changes was assessed, subgrouped by GA foveal involvement or focality. Time-to-event analysis for BCVA loss of ≥5, ≥10, and ≥15 letters was performed. A Cox regression model adjusted for baseline factors was performed on these outcomes. Kaplan-Meier curves are provided for each baseline factor and GA growth rate.

MAIN OUTCOME MEASURES:

Correlations of baseline BCVA, GA area, and growth rate with change in BCVA, and time to ≥5, ≥10, and ≥15-letter loss by foveal involvement or focality.

RESULTS:

Best-corrected visual acuity and GA area at baseline did not correlate with BCVA change at any visit. Geographic atrophy growth rate showed a weak correlation with BCVA loss, which increased over time. The 2 highest GA growth rate quartiles had accelerated BCVA loss in eyes with subfoveal, unifocal lesions. Approximately 75%, 50%, and 25% of study eyes experienced a ≥5-, ≥10-, and ≥15-letter loss by 2 years, respectively.

CONCLUSIONS:

Best-corrected visual acuity and GA area at baseline did not correlate with BCVA loss, but faster GA growth rates appeared to be associated with faster BCVA loss. Geographic atrophy foveal involvement and focality correlated with the rate of BCVA loss with subfoveal lesions at high risk of vision loss over time, especially when the GA lesion was unifocal.

FINANCIAL DISCLOSURE(S):

Proprietary or commercial disclosure may be found after the references.

2025-03-01·Ophthalmology science

Deep Learning to Predict the Future Growth of Geographic Atrophy from Fundus Autofluorescence

Article

作者: Yang, Qi ; Ferrara, Daniela ; Holz, Frank G ; Schiffman, Courtney ; Salvi, Anish ; Sadda, Srinivas R ; Cluceru, Julia ; Anegondi, Neha ; Rabe, Christina ; Lee, Aaron Y ; Keane, Pearse A ; Gao, Simon S

Purpose:

The region of growth (ROG) of geographic atrophy (GA) throughout the macular area has an impact on visual outcomes. Here, we developed multiple deep learning models to predict the 1-year ROG of GA lesions using fundus autofluorescence (FAF) images.

Design:

In this retrospective analysis, 3 types of models were developed using FAF images collected 6 months after baseline to predict the GA lesion area (segmented lesion mask) at 1.5 years, FAF images collected at baseline and 6 months to predict the GA lesion at 1.5 years, and FAF images collected 6 months after baseline to predict the GA lesion at 1 and 1.5 years. The 1-year ROG from the 6-month visit was derived by taking the difference between the GA lesion area (segmented lesion mask) at the 1.5-year and 6-month visits.

Participants:

Patients enrolled in the following lampalizumab clinical trials and prospective observational studies: NCT02247479, NCT02247531, NCT02479386, and NCT02399072.

Methods:

Datasets of study eyes from 597 patients were split into model training (310), validation (78), and test sets (209), stratified by baseline or initial lesion area, lesion growth rate, foveal involvement, and focality. Deep learning experiments were performed using the 2-dimensional U-Net; whole-lesion and multiclass models were developed.

Main Outcome Measures:

The performance of the models was evaluated by calculating the Dice score, coefficient of determination (R²), and the squared Pearson correlation coefficient (r²) between the true and derived GA lesion 1-year ROG.

Results:

The model using baseline and 6-month FAF images to predict GA lesion enlargement at 1.5 years had the best performance for the derived 1-year ROG. Mean Dice scores were 0.73, 0.68, and 0.70 in the training, validation, and test sets, respectively. The R² (0.77, 0.53, and 0.79) and r² (0.83, 0.61, and 0.79) showed similar trends across the 3 sets.

Conclusions:

These findings show the potential of using baseline and/or 6-month visit FAF images to predict 1-year GA ROG using a deep learning approach. This work could potentially help support decision-making in clinical trials and more informed treatment decisions in clinical practice.

Financial Disclosures:

Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

项与 Lampalizumab 相关的新闻（医药）

2024-08-01

·FierceBiotech

Ionis axes eye disease from targets of Roche-partnered prospect after data disappoint

Ionis Pharmaceuticals disclosed the news it no longer sees a future for one of its assets in geographic atrophy alongside confirmation that ION541, an amyotrophic lateral sclerosis candidate, is no longer part of its plans. Another of Ionis Pharmaceuticals’ key midphase readouts has fallen short of expectations, prompting the biotech to stop studying the Roche-partnered candidate in an advanced form of age-related macular degeneration. Roche exercised its option on the drug candidate, which is variously called IONIS-FB-LRx, RO7434656 and RG6299, in 2022. The Swiss drugmaker took responsibility for global development, with the exception of an open-label phase 2 IgA nephropathy (IgAN) trial and a phase 2 study in geographic atrophy (GA). In June, Ionis identified the GA readout as one of the key value-driving events planned for 2024.The event failed to drive value. Rather, Ionis stopped development of the candidate in GA after seeing the results of the 332-patient phase 2 study that wrapped up in June. Ionis said it saw “favorable safety profiles and good target engagement, but insufficient efficacy to advance into phase 3 development.”Roche is continuing to enroll patients in its phase 3 IgAN study, and data from the open-label trial in the chronic kidney disease remains on Ionis’ road map for the year. But Ionis no longer sees a future for the asset in GA. Ionis’ interest in testing the drug in the eye disease reflected evidence that the alternative complement pathway is linked to GA. Overproduction of complementing factor B, an activating factor in the pathway, is associated with higher risk. Roche targeted similar biology with complement factor D-binding antibody fragment lampalizumab only to see the candidate fail a phase 3 clinical trial in GA in 2017.Lampalizumab was administered into the eye. With most factor B produced in the liver, Ionis gave its GA drug candidate systemically to try to stop the accumulation of the complement factor and the resulting destruction of the macula. Ionis CEO Brett Monia, Ph.D., acknowledged that rationale may fail to translate into an effective drug at a TD Cowen investor event in June.“It's a significantly risky program. But on the other hand, the upside is enormous, since this drug would not have to be intravitreally administered, it would be injected using a simple auto-injector once per month by the patient themselves,” Monia said. “It could be a real breakthrough, game changer for this indication, but it does not come without risk.”Ionis disclosed the failure of IONIS-FB-LRx to live up to that billing alongside confirmation that ION541 is no longer part of its plans. The biotech and partner Biogen reported the termination of development of the amyotrophic lateral sclerosis candidate, which is also called BIIB105, in May after seeing phase 1/2 data.

临床2期临床3期

2022-02-09

·生物制药小编

眼科治疗蓝海市场，补体药物正当时

近两年，补体药物临床开发不断取得积极进展，一些罕见病患者已经充分从中受益。在罕见病之外，补体药物在眼科等常见病的开发应用逐渐活跃起来。 1、三条路径临床转化补体系统不仅是机体发挥天然免疫防御的重要效应机制，同时也是主要的体液免疫效应机制之一。当补体系统参与防卫时，会迅速产生大量的补体前体蛋白来响应和检测威胁，对消除外来抗原的侵害，对维护机体内环境的平衡具有重要作用。补体系统的整个活化过程表现为一系列丝氨酸蛋白酶的级联酶解反应，最终形成膜攻击复合物导致靶细胞损伤。补体系统的活化主要通过经典途径（Classical pathway），旁路途径（Alternative pathway）和凝集素途径（Lectin pathway），3条既相对独立又相互联系的途径实现，三条途径产生的C5转化酶，均可裂解C5，引发共同终末效应，进而发挥调理吞噬、裂解细胞、介导炎症、免疫调节和清除免疫复合物等多种生物学效应。不过，补体的失衡可造成广泛的组织器官损伤，牵连甚广。补体异常过度激活可引发阵发性睡眠性血红蛋白尿(PNH)、老年性黄斑变性(AMD)，重症肌无力(gMG)等CNS/PNS疾病，非典型溶血尿毒综合征(aHUS)、C3肾小球病(C3G)和IgA肾病等肾脏疾病、血栓性微血管病(TMAs)等多种疾病。鉴于补体系统显著的致病作用，近年来，各种补体效应物作为药物开发靶点逐渐受到重视。三条路径均已逐渐往临床应用方向转化。FDA在2007年批准了首款补体药物Soliris上市，用于治疗PNH。作为一款罕见病用药，Soliris的销售业绩却十分亮眼。上市以来，Soliris累计销售额200亿美元，为Alexion现金牛产品。Alexion在不断拓展Soliris的新适应症的基础上，2018年，Alexion又推出Soliris的升级版产品Ultomiris。尽管有了成功的商业化先例，但过去获批的补体药物数量仍然十分稀少。2021年前，FDA累计批准了仅两款补体药物。近两年来，随着对补体系统整个了解的加深，补体药物开发取得重要进展。去年至今，FDA已经批准了三款产品。2021年5月，FDA批准了一款新的补体药Empaveli，用于治疗PNH，为近15年迎来的新型补体药。10月7日，FDA又批准了首款C5a受体抑制剂的口服药Tavneos，用于两种主要的抗中性粒细胞胞浆自身抗体（ANCA）相关血管炎—显微镜下多血管炎（MPA）和肉芽肿伴多血管炎（GPA）的辅助治疗。上周（2022年2月4日），赛诺菲补体C1s抗体Sutimlimab（商品名为Enjaymo）获得FDA批准，用于治疗冷凝集素病。 2、眼科疾病开发进展虽然目前市场上的补体药物适应症均为罕见病，但在眼科中的应用早有尝试，特别在干性AMD的眼科疾病中，补体理论是当下最主流的治疗机理。有研究揭示，补体途径的活化不仅参与了AMD的发生和发展，并可能参与了视网膜萎缩和纤维化的病理过程。因此，罕见病之外，针对眼科的补体类药物开发逐渐开始有了尝试，包括涉及补体系统的一些常见熟悉靶点C5，C3以及补体系统中一些不知名陌生靶点，D因子，FB等， Zimura和pegcetacoplan是两款进展最快的治疗药物。 Zimura（avacincaptad pegol）为VERIC bio公司重点针对眼科开发的一款C5抑制剂，通过抑制补体因子C5的切割和末端片段C5a和C5b的形成，来减少调控炎症的多种蛋白的激活并减缓视网膜色素上皮细胞RPE变性，从而缓解GA-AMD疾病的进展。2020年，VERIC在Ophthalmology期刊上公布了Zimura临床数据，Zimura在AMD相关继发性地图样萎缩(GA)的Ⅲ期临床GATHER1中达到了预设的主要终点。与对照组相比，12个月内，4mg和2mg Zimura剂量组患者地图状萎缩病变速度分别降低27.81%和27.38%，耐受性良好。 Apellis开发了一款合成环肽pegcetacoplan，特异性地与C3和C3b结合，是目前在临床中显示对GA治疗效果最好的候选产品。此前，pegcetacoplan在GA的Ⅱ期临床中取得了成功，临床试验结果证明其能减慢40%GA的进程。去年，pegcetacoplan治疗PNH的适应症已经获得批准上市。去年10月27日，Sobi以总价值12亿美元引进了pegcetacoplan非美地区商业权益。 NGM Biopharmaceuticals公司开发了一款靶向C3单抗NGM621，目前正在一项Ⅱ期临床中进行评估，预计将于近年第四季度获得顶线数据。2022年2月7日，NGM621获得FDA授予快速通道资格。另一方面，补体虽然是当下干性AMD较为主流的治疗理论。不过，鉴于这种疾病机制尚不明确，研发难度甚大，此前Alexion也曾将它的明星产品Soliris和罗氏/基因泰克的补体因子D抑制剂Lampalizumab几款基于补体理论的临床试验以失败告终。国内方面，补体领域的新药开发相对冷清，多在初步尝试阶段。目前已公开披露的在眼科方面有补体开发意向不过三五家。信达生物自主研发一款抗VEGF-抗补体双靶点药物IBI302，以同时抑制VEGF介导的信号通路和减轻补体活化介导的炎症反应。2021年4月29日，信达宣布IBI302已完成针对wAMD 的Ⅱ期临床首例患者给药。另外国内天辰生物在补体的眼科应用已有布局，有一款补体药物RX-001（具体靶点未披露）。2021年4日25日，天辰生物宣布与艾尔健康就RX-001眼科治疗达成了一项价值10亿元的全球授权合作协议。 3、总结抗VEGF药物是目前wAMD等在内眼底新生血管病治疗的主旋律，实现了大多数眼底新生血管病患的视力改善，使原来几乎不能治疗的眼底疾病得到了有效控制和治疗。相比之下，占到AMD80%以上的干性AMD市场仍处于空白，目前尚无任何有效治疗和预防药物。补体药物作为当下集中干性AMD治疗中坚力量，在通过临床验证之后，等待的将是4/5倍于wAMD的巨大市场。内容来源于网络，如有侵权，请联系删除，谢谢。

抗体快速通道合作

2021-09-09

·Endpoints

Apellis turns up mixed results in closely watched eye disease tests. Are the data strong enough for approval?

Looking to scuffle with rare disease giant and now AstraZeneca subsidiary Alexion, little Apellis scored a breakthrough win earlier this summer for its own complement factor inhibitor drug. Apellis, though, always had its eyes on bigger fish, but a first glimpse at pivotal data for a major indication has muddied the waters. In two Phase III studies testing pegcetacoplan in patients with geographic atrophy, Apellis’ drug nailed the primary endpoints in one test but flopped the same checkpoints in a “carbon copy” study, according to topline data released Thursday. Geographic atrophy is an advanced form of dry age-related macular degeneration with no approved therapies that affects around 5 million patients worldwide — including around 1 million in the US — and is a leading cause of blindness. An approval here could spell blockbuster sales for pegcetacoplan, a complement C3 inhibitor now marketed as Empaveli for paroxysmal nocturnal hemoglobinuria (PNH) — which is exactly why analysts and investors have kept such a close eye on these studies. In June, Evaluate Pharma pegged the drug’s potential market in GA at $1.2 billion in 2026. In the Phase III OAKS trial, pegcetacoplan injected in the eye reduced the rate of GA lesion growth by 22% (p=0.0003) and 16% (p=0.0052) compared with pooled sham injection in patients administered a monthly and once-every-other-month dose of the drug, respectively, after a year, Apellis said. Taken alone, that’s great news for Apellis. But the second trial toplined Thursday — the Phase III DERBY study — painted a murkier picture of the drug’s efficacy. In that trial, pegcetacoplan failed to significantly cut lesion growth rate compared with sham in both cohorts, posting rates of 12% (p=0.0528, just over the standard benchmark of p=0.05) and 11% (p=0.075), respectively. That’s a concern since the studies were mirror images of one another and offered contradicting pictures of whether Apellis’ drug works in this indication. In an attempt to bridge the gap between the two studies, Apellis offered results from a prespecified analysis combining the primary endpoints from both studies to determine overall significance. The biotech said monthly doses of the drug in both studies cut lesion growth by 17% overall (p=<0.0001) and a once-every-other-month dose cut lesion growth by 14% (p=0.0012) compared with sham. A failed study is a black mark on any drug’s record, but CEO Cedric Francois said the totality of pegcetacoplan’s efficacy and safety data — which includes results from the Phase II FILLY trial — could offer a compelling case for regulators. The company expects to file for approval as soon as the first half of 2022. “You have to look at these data in terms of the totality of data that we have assembled,” he told Endpoints News . “The entire data package that we have presents a very strong case for approval.” In terms of why the studies diverged so greatly, Francois didn’t have much to offer, saying: “If you run the same trial 20 times, you’ll get 20 different results.” Francois highlighted the safety data for pegcetacoplan in DERBY and OAKS, with just 6% of patients reporting exudations from the eye in the monthly dose cohorts and 4.1% in the every-other-month cohorts. There were two confirmed cases of infectious endophthalmitis and another suspected case among 6,331 injections administered during the studies. Meanwhile, there were 13 cases of intraocular inflammation reported and no retinal vasculitis or retinal vein occlusion reported. “We came into this program with a drug that we believed would have to be given every month to patients, where there was concern that we may have an increased rate of exudation that was going to be a problem,” Francois said. “The safety here is so good that this is a drug that you’ll want to give to all patients with GA.” Another potential boon to the drug’s case was its effect on what are called extrafoveal lesions, which are early signs of the disease prior to central vision being affected. In a combined exploratory analysis, pegceptacoplan cut the rate of growth for those lesions by 26% (p=<0.0001) for the once-monthly cohorts and 23% (p=0.0002) for the once-every-month cohorts. So that leaves the ball in the FDA’s court, and it’s unclear exactly how regulators will absorb these conflicting results. It wouldn’t be the first time that missing a primary endpoint hasn’t torpedoed a drug’s chances, and the unmet clinical need and strong safety data could be enough to push the drug over the finish line. If the FDA does cooperate, it would be the culmination of Apellis’ yearslong drive for GA, a disease Francois described as a “forest fire” in the eye that has so far confounded drug developers. Way back in 2017, Roche saw its own chances in GA collapse after its antibody lampalizumab flopped a key test in GA patients. But Apellis believes complement factor inhibition could be key, which explains why Alexion — now a part of AstraZeneca — has been dabbling here with its own C5 inhibitor franchise. Empavelis’ approval in PNH in May marked the first major challenge to Alexion’s Soliris, a blockbuster drug for which PNH is the single largest indication. Prior to its acquisition, Alexion was busy switching most of its patients over to follow-up drug Ultomiris, which sports a matching PNH approval and is working to quickly expand its label to match the older drug.

抗体并购

100 项与 Lampalizumab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10440	Lampalizumab	-	DB11826

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
年龄相关性黄斑变性	临床3期	美国	Hoffmann-La Roche, Inc.	2014-09-18
年龄相关性黄斑变性	临床3期	阿根廷	Hoffmann-La Roche, Inc.	2014-09-18
年龄相关性黄斑变性	临床3期	澳大利亚	Hoffmann-La Roche, Inc.	2014-09-18
年龄相关性黄斑变性	临床3期	奥地利	Hoffmann-La Roche, Inc.	2014-09-18
年龄相关性黄斑变性	临床3期	比利时	Hoffmann-La Roche, Inc.	2014-09-18
年龄相关性黄斑变性	临床3期	加拿大	Hoffmann-La Roche, Inc.	2014-09-18
年龄相关性黄斑变性	临床3期	丹麦	Hoffmann-La Roche, Inc.	2014-09-18
年龄相关性黄斑变性	临床3期	法国	Hoffmann-La Roche, Inc.	2014-09-18
年龄相关性黄斑变性	临床3期	德国	Hoffmann-La Roche, Inc.	2014-09-18
年龄相关性黄斑变性	临床3期	匈牙利	Hoffmann-La Roche, Inc.	2014-09-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02247479 (CHROMA, CTgov)	临床3期	年龄相关性黄斑变性 \| 地图样萎缩	906	Sham	繭壓壓蓋鹽築蓋獵齋淵(憲範蓋觸範齋鹹選艱選) = 顧鑰衊鹹憲壓鹽繭鑰鏇膚壓襯壓窪襯憲願網繭 (選獵糧簾衊蓋繭壓餘壓, 0.066) 更多	-	2019-04-23
NCT02247531 (SPECTRI, CTgov)	临床3期	年龄相关性黄斑变性 \| 地图样萎缩	975	Sham Comparator	範網鏇鬱醖繭願廠衊鏇(廠遞積襯蓋蓋製壓餘遞) = 觸壓築觸鬱餘糧艱觸襯鹹餘製製獵鑰糧齋鑰製 (獵獵積齋齋鏇淵廠顧遞, 0.056) 更多	-	2019-03-14
NCT01602120 (CTgov)	临床2期	地图样萎缩	159	Lampalizumab (CFD4870g Sham)	範鬱獵糧簾艱願積鏇夢 = 糧餘齋糧鬱遞壓艱艱願鹹蓋繭衊艱鬱齋觸簾鑰 (築願蓋廠衊膚餘製衊獵, 壓醖顧遞鏇鏇醖淵憲蓋 ~ 鬱鏇築構衊選衊網範鬱) 更多	-	2019-02-21
				Lampalizumab (CFD4870g Lampalizumab)	範鬱獵糧簾艱願積鏇夢 = 齋範觸齋鹹鑰構鑰積窪鹹蓋繭衊艱鬱齋觸簾鑰 (築願蓋廠衊膚餘製衊獵, 鹽餘廠廠網夢壓襯觸艱 ~ 繭襯襯齋廠窪遞淵廠糧) 更多
NCT02745119 (CTgov)	临床3期	年龄相关性黄斑变性 \| 地图样萎缩	994	Lampalizumab (Lampalizumab Q4W - Treatment-Naive)	齋網夢選築鹽鹹糧衊積 = 衊鹹觸鹹衊築憲鹹製繭襯齋齋顧壓蓋繭齋鹽範 (襯簾觸艱淵廠築廠鬱顧, 膚構網網淵積鏇蓋餘廠 ~ 獵鏇願鹽製蓋艱蓋選餘) 更多	-	2019-02-15
				Lampalizumab (Lampalizumab Q4W - Previously Treated)	齋網夢選築鹽鹹糧衊積 = 鏇鹽齋顧觸網製醖蓋製襯齋齋顧壓蓋繭齋鹽範 (襯簾觸艱淵廠築廠鬱顧, 膚壓醖鑰繭鹹糧鹹製淵 ~ 觸鏇壓衊襯製製淵淵鏇) 更多
NCT02247479 \| NCT02247531 (Chroma and Spectri, ARVO2018)	临床3期	年龄相关性黄斑变性 complement factor I (CFI)-profile	-	Lampalizumab every 4 weeks	襯憲窪鏇獵艱製憲齋鹽(遞齋鏇淵壓膚醖鑰繭窪) = 製鏇鏇製衊選願鏇鹽鹹鬱簾鏇夢夢壓衊餘顧繭 (簾選襯觸艱範夢顧網鬱 )	不佳	2018-07-01
				Lampalizumab every 6 weeks	襯憲窪鏇獵艱製憲齋鹽(遞齋鏇淵壓膚醖鑰繭窪) = 獵夢襯繭衊蓋壓構積衊鬱簾鏇夢夢壓衊餘顧繭 (簾選襯觸艱範夢顧網鬱 )
NCT02247479 \| NCT02247531 (Chroma and Spectri, Pubmed \| JAMA Ophthalmol)	临床3期	年龄相关性黄斑变性	1,881	Lampalizumab 10 mg every 4 weeks	糧觸糧膚製糧願積襯鹽(壓鹹積淵餘獵夢願襯簾) = Endophthalmitis occurred after 5 of 12,447 injections (0.04%) or in 5 of 1,252 treated participants (0.4%) through week 48 餘窪壓顧鑰糧鑰簾鹹壓 (築夢鏇鹹網蓋繭壓艱網 )	不佳	2018-06-01
				Lampalizumab (Sham procedure every 4 weeks)